# SynCardia Systems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syncardia-systems

- Industry: Medical Devices & Equipment
- Headquarters: Tucson, US
- Website: www.syncardia.com
- Total disclosed funding: $15M
- Latest round: Series E (Mar 28, 2011)
- Investors on record: 3

## About

SynCardia Systems, Inc. develops innovative medical technologies, focusing on the SynCardia Total Artificial Heart, the first device that fully replicates human heart functions for patients with severe heart failure.Founded in 2001, SynCardia Systems, Inc. is headquartered in Tucson, US, and specializes in advanced heart replacement technologies. The company has raised a total of USD 6.41 mn, with its latest funding round in 2023 amounting to USD 6.41 mn. The CEO team comprises Don Webber and Patrick Schnegelsberg, reflecting a blend of leadership experience in the medical technology sector. The company has completed 11 deals throughout its history.SynCardia Systems, Inc. specializes in advanced heart replacement technology, specifically the SynCardia Total Artificial Heart (STAH), which is the first and only commercially available device that fully replicates the functions of a human heart. This innovative product is designed to provide a temporary heart solution for patients suffering from end-stage biventricular heart failure, effectively prolonging and enhancing the quality of life while they await a suitable heart transplant. The STAH is available in two sizes to accommodate a wide range of patients, and it has been successfully implanted over 2,000 times in more than 20 countries, including the United States, Germany, and Japan. SynCardia's client base includes hospitals, cardiac transplant centers, and medical professionals who treat patients with severe heart conditions, and the company prides itself on delivering a life-saving solution to those at risk of imminent death due to heart failure.Revenue generation for SynCardia Systems, Inc. is primarily driven by the sales of its flagship product, the SynCardia Total Artificial Heart, to medical institutions and healthcare providers. The company operates on a direct sales model, engaging hospitals and cardiac care centers that are responsible for the implantation and management of the artificial heart. These transactions typically involve the purchase of the artificial heart device, along with associated support services and training for medical staff. SynCardia's pricing structure is reflective of the extensive research and development invested in their patented technology, particularly in the context of complex medical devices that require significant regulatory approval and clinical validation. As a result, the revenue streams are concentrated around B2B transactions with healthcare providers rather than direct consumer sales.SynCardia Systems, Inc. is focused on enhancing its product offerings and expanding into new markets. The company is currently designing new advancements to the SynCardia Total Artificial Heart, aiming for a release in the coming years. Plans are underway to target additional markets in Europe and Asia by 2025. The recent funding of USD 6.41 mn will support these development initiatives, allowing the company to further its research, product features, and market expansion efforts.

## Funding rounds

- Series E, Mar 28, 2011, $1.4M — Highway 12 Ventures, Seneca Partners, Solstice Capital
- Series E, Jan 21, 2011, $3.6M — Highway 12 Ventures, Seneca Partners, Solstice Capital
- Series D, Jun 24, 2009, $10M — Highway 12 Ventures

## Investors

- Highway 12 Ventures (https://capitalatlas.ai/funds/highway-12-ventures) — Series D, Series E
- Seneca Partners — Series E
- Solstice Capital (https://capitalatlas.ai/funds/solstice-capital) — Series E